Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 20.84 USD 2.32% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Schrodinger Inc
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Schrodinger Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
Other Current Assets
$22.9m
CAGR 3-Years
39%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Other Current Assets
$78.6m
CAGR 3-Years
33%
CAGR 5-Years
29%
CAGR 10-Years
29%
Inspire Medical Systems Inc
NYSE:INSP
Other Current Assets
$14.4m
CAGR 3-Years
69%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Other Current Assets
$42.6m
CAGR 3-Years
37%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Other Current Assets
$72.6m
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
7%
W
Waystar Holding Corp
NASDAQ:WAY
Other Current Assets
$53.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 664 full-time employees. The company went IPO on 2020-02-06. The firm operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. The Company’s physics-based software platform enables discovery of molecules for drug development and materials applications. Its software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company’s pipeline includes CDC7, Wee1, MALT1, HIF-2 alpha and SOS1/KRAS. Its CDC7 is a small molecule inhibitor for treatment of solid and liquid tumors.

SDGR Intrinsic Value
14.65 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Schrodinger Inc's Other Current Assets?
Other Current Assets
22.9m USD

Based on the financial report for Sep 30, 2024, Schrodinger Inc's Other Current Assets amounts to 22.9m USD.

What is Schrodinger Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
46%

Over the last year, the Other Current Assets growth was 19%. The average annual Other Current Assets growth rates for Schrodinger Inc have been 39% over the past three years , 46% over the past five years .

Back to Top